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Abstract
Background: Although maternal serum alpha-fetoprotein (MSAFP) is a highly sensitive marker for
certain congenital malformations such as open neural tube and ventral wall defects, its usefulness
as a screening test for fetal hydrocephalus is uncertain. We wished to determine the distribution
of maternal serum alpha-fetoprotein levels associated with fetal hydrocephalus in a population-
based screening program in Manitoba, and their potential relationship to additional anomalies.
Methods: Cases of fetal hydrocephalus unrelated to neural tube defects were ascertained from
multiple sources and reviewed. Cross-reference with the Manitoba Maternal Serum Screening
Program database determined which mothers had undergone maternal serum screening. Mean
MSAFP levels in both isolated and complex hydrocephalus were calculated and compared with the
general population of screened pregnancies using Independent Samples T-tests.
Results: Mean MSAFP levels in 70 cases of fetal hydrocephalus were significantly higher than those
of the general population of screened pregnancies (P = 0.029). This was due to the fact that mean
MSAFP levels in those cases with other major anomalies were increased over those of the general
population (P = 0.041); cases with hydrocephalus alone showed no significant difference (P = 0.203).
Only seven cases (10%) had MSAFP levels ≥ 2.3 multiples of the median, the cut-off used in
Manitoba. However, six of these (86%) had additional major and/or minor malformations.
Conclusion: MSAFP screening has low sensitivity for fetal hydrocephalus and is rarely elevated in
isolated cases. However, when fetal hydrocephalus is detected, elevated MSAFP levels indicate that
the fetus is at significant risk to have additional malformations and further investigations, including
chromosome breakage studies, may be indicated.
Background
Although maternal serum alpha-fetoprotein (MSAFP) is a
highly sensitive marker for certain congenital malforma-
tions such as open neural tube and ventral wall defects, its
usefulness as a screening test for fetal hydrocephalus is
uncertain. Since Seppala and Unnerus [1] first noted the
possible association between elevated amniotic fluid
alpha-fetoprotein (AFAFP) levels and fetal hydrocephalus,
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there have been relatively few reports of AFP levels in such
cases. The purpose of this retrospective, population-based
study was to determine the relationship between MSAFP
levels and fetal hydrocephalus in women undergoing rou-
tine maternal serum screening.
Methods
After approval had been obtained from the University of
Manitoba Health Research Ethics Board, multiple sources
including the Manitoba Maternal Serum Screening Pro-
gram (MMSSP) pregnancy outcomes database, the Section
of Genetics and Metabolism (now the Genetics and
Metabolism Program of the Winnipeg Regional Health
Authority) records and the Health Sciences Centre, Winni-
peg patient database were utilized to ascertain all cases
where hydrocephalus had been diagnosed prenatally or
shortly after birth (termed fetal hydrocephalus) and
where the mother's estimated date of delivery had been
between January 1, 1985 and December 31, 2001. The
records of the MMSSP were then used to determine in
which of these cases maternal serum screening had been
performed on the mother. The year 1985 was chosen as
the start date for ascertainment because that was the year
in which the MMSSP (formerly the Manitoba Maternal
AFP Screening program) became a formal provincial pro-
gram, providing screening on request to all residents at no
charge. Chart review of cases also documented informa-
tion on additional malformations so that MSAFP analyses
on the subgroups of both isolated and complex fetal
hydrocephalus could be performed. Cases of hydrocepha-
lus in association with a neural tube defect and those in
multiple gestation pregnancies were excluded from the
study because of the known associations with elevated
MASFP.
The control group used in the MSAFP analysis included all
singleton pregnancies screened by the MMSS program in
Manitoba between 1990 and 2001 inclusively (1990 was
the first year that computerized records were kept), in
which the mother was not known to be diabetic. Mothers
with insulin-dependent diabetes mellitus were removed
from the control group to allow easier comparison with
other studies, many of which use different methods to
control for the slower rise in MSAFP in women with this
condition.
The SPSS 11.5 Independent-Samples T-test (also known
as the two sample t-test) was used to compare the mean
MSAFP values of all cases and controls. Mean MSAFP lev-
els for both the subgroup of cases of complex fetal hydro-
cephalus and the subgroup of cases of isolated fetal
hydrocephalus were also compared to the control group.
In addition, mean MSAFP levels in complex and isolated
cases were compared. MSAFP levels are reported in multi-
ples of the median (MoM) so values can theoretically
range from zero upward, with the expected median being
about 1.0 MoM. Because of this, distributions derived
from MSAFP data are characteristically skewed to the
right. To normalize the distributions and allow use of the
parametric T-test, the log of the MoM values of all MSAFP
data was used in the analysis. The sensitivity of MSAFP
screening as a predictor for fetal hydrocephalus was estab-
lished by calculating what proportion of screened cases
fell at or above 2.3 MoM.
Results
Between 1998 and 2001 inclusively, there were 281,288
livebirths and stillbirths in Manitoba, while 155,518 preg-
nancies or approximately 55% were screened by MSAFP.
A total of 131 cases of fetal hydrocephalus with no associ-
ated neural tube defect were ascertained, giving a minimal
incidence of 4.66/10,000 total births. Of the 131 cases, 73
(56%) had MSAFP data available. Three cases with MSAFP
data were excluded from the study due to twin pregnan-
cies leaving 70 for analysis. Of these, 40 cases were of
complex fetal hydrocephalus with additional major and/
or minor malformations identified, while 30 cases were of
isolated hydrocephalus.
Four different T-tests were performed (Table 1). The first,
comparing the MSAFP values of all cases of fetal hydro-
cephalus to those of the control population, indicated a
significant increase in the hydrocephalus cases. The sec-
ond, comparing MSAFP levels in the subgroup of cases
with complex fetal hydrocephalus to controls was also sig-
nificant. The third T-test, comparing the subgroup of cases
Table 1: Group statistics and T-test results of MSAFP analysis
T-test N Mean MoM Mean of Log values T-test P-value
All cases
Controls
70
91,541
1.34
1.14
0.0727
0.0231
0.029
Complex cases
Controls
40
91,541
1.44
1.14
0.0910
0.0231
0.041
Isolated cases
Controls
30
91,541
1.20
1.14
0.0484
0.0231
0.203
Isolated cases
Complex cases
30
40
1.20
1.44
0.0484
0.0910
0.198BMC Pregnancy and Childbirth 2006, 6:23 http://www.biomedcentral.com/1471-2393/6/23
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of isolated hydrocephalus to the control population, and
the fourth, comparing complex and isolated fetal hydro-
cephalus cases, showed no significant differences.
In Manitoba, MSAFP values of 2.3 MoM or greater are cur-
rently considered elevated and warrant fetal assessment.
Of the cases of fetal hydrocephalus that had MSAFP test-
ing performed, 10.0% (7 cases) fell at or above this cut-
off. These seven cases are summarized in Table 2.
Discussion
Since Seppala and Unnerus [1] first suggested a possible
association between elevated AFP levels and fetal hydro-
cephalus, there has been a relative lack of information
about the subject in the literature. Most of the informa-
tion is in case reports based on few patients [2-14]. One of
the strengths of the present study is that its focus is a large,
population-based sample of cases of fetal hydrocephalus.
Seppala and Unnerus [1] postulated that the increase in
amniotic fluid alpha-fetoprotein levels that they observed
in four cases of fetal hydrocephalus might be due to pas-
sage of AFP-containing cerebral spinal fluid across the
greatly thinned fetal skull into the amniotic cavity. In such
cases, excess AFP in the amniotic fluid might pass into the
maternal serum by diffusion across the placenta and fetal
membranes. However, none of their patients had elevated
MSAFP levels and at least one other report [3] failed to
document even an elevation of AFAFP.
An alternative hypothesis would be that elevations of
MSAFP in fetal hydrocephalus may be due to other unde-
tected malformations. Previously, we reported four
infants in whom hydrocephalus was identified during a
fetal assessment performed for elevated MSAFP and who
were found at birth to have VACTERL-H or other patterns
of multiple anomalies [14]. (VACTERL-H is a heteroge-
nous condition where hydrocephalus occurs in conjunc-
tion with two or more anomalies seen in the Vertebral-
Anal-Cardiac-Tracheo-Esophageal-Renal-Limb associa-
tion. Although many cases are apparently sporadic, both
sex-linked and autosomal recessive forms exist and exces-
sive chromosome breakage has been documented in
both.) Esophageal atresia was present in all four of these
cases, but not identified until birth in any of them. This
malformation was singled out as a possible cause of the
MSAFP elevations as we had previously documented an
association between esophageal atresia and elevated
MSAFP and hypothesized that impaired swallowing
might prevent reabsorption of AFAFP[15]. Impaired renal
function is another potential cause of elevated MSAFP and
several sets of siblings with both congenital nephropathy
and hydrocephalus or ventriculomegaly have been
reported [16]; [17]; [18]. In cases of this apparently auto-
somal recessive condition, MSAFP levels have consistently
been extremely high (>8.0 Mom).
Our present study has determined that, on a population
basis, MSAFP levels are significantly higher in cases of fetal
hydrocephalus than in the general population of screened
pregnancies. Repeating this analysis using subgroups of
isolated and complex hydrocephalus reveals that only
complex cases show a significant increase in mean MSAFP
levels, suggesting that the elevation in MSAFP levels may
well be due to the other malformations present in some
cases.
These data represent the first population-based analysis of
MSAFP levels in fetal hydrocephalus and confirm that, as
suggested by the previous case reports, mean MSAFP lev-
els are significant higher in this group of malformed
fetuses. The more pertinent statistic from a clinical stand-
Table 2: Summary of cases with elevated MSAFP levels
Case number MSAFP levels (MoM) Associated findings
1 4.3 Patent ductus arteriosus, patent foramen ovale, dysmorphic skull, low set left ear
2* 2.3 Cystic hygroma, left pleural effusion, cardiac anomalies (unspecified), abnormal limb position, 
oligohydramnios
3 3.2 Epicanthic folds, hypertelorism, short nose with a long philtrum, hypoplastic toenails
4** 2.9 Cerebral dysgenesis, ascites, cardiac hypertrophy, amputation of both hands and feet, ambiguous 
external genitalia
5*** 2.7 Esophageal atresia, tracheo-esophageal fistula, hemivertebrae, absent septum pellucidum, choroid 
plexus cyst
6*** 2.6 Agenesis of corpus callosum, hypoplastic cerebellum, abnormal cerebrum, down slanting palpebral 
fissures, microphthalmia, micrognathia, thin distally placed thumbs, esophageal atresia, tracheo-
esophageal fistula, C7 hemivertebrae, thoracic scoliosis, abnormal lung lobation, large left liver lobe, 
bilateral renal dysplasia with hydronephrosis and hydroureters, sacral dimple
7 2.5 None
* Final diagnosis: trisomy 21
** Final diagnosis: amnion disruption sequence
*** Final diagnosis: VACTERL-H syndromeBMC Pregnancy and Childbirth 2006, 6:23 http://www.biomedcentral.com/1471-2393/6/23
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point is sensitivity. In the present study, only 10% of cases
had had values ≥ 2.3 MoM, our current cut off for further
investigation, which is even lower than the 25% sensitiv-
ity reported by Burton [19]. However, six of our seven
cases had associated major and/or minor malformations
and two had obvious VACTERL-H with esophageal atresia
among their spectrum of anomalies.
The most likely explanation for high MSAFP in a preg-
nancy where fetal hydrocephalus is detected is spina bif-
ida. However, if this is ruled out, these fetuses remain at
risk to have additional malformations and should be
monitored closely should the pregnancy be continued.
Fetal hydrocephalus is normally considered a high risk sit-
uation. Our results indicate that the concomitant finding
of elevated MSAFP warrants consideration of chromo-
some breakage studies in addition to standard karyotyp-
ing as Fanconi anemia [20]; [21], X-linked VACTERL-H
[22] and Nijmegen breakage syndrome [23] may all
present with both excess breaks and hydrocephalus. As
well, detailed serial fetal assessments and detailed neona-
tal evaluation should be performed as some malforma-
tions such as esophageal atresia can be difficult to detect
while others such as hydronephrosis or mild radial ray
deficiency may only be evident later in gestation or post-
natally. Awareness that a syndromal diagnosis is possible
may help ensure that the family receives appropriate
counselling with respect to prognosis and recurrence risk.
Conclusion
MSAFP screening has low sensitivity for fetal hydrocepha-
lus and is rarely elevated in isolated cases. However, when
fetal hydrocephalus is detected, elevated MSAFP levels
indicate that the fetus is at significant risk to have addi-
tional malformations and further investigations, includ-
ing chromosome breakage studies, may be indicated.
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